Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#101 / 200 Total
ALLO - Allogene Therapeutics Inc - Stock Price Chart
TickerALLO [NASD, RUT]
CompanyAllogene Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap367.18MEPS (ttm)-1.34
P/E-EPS this Y9.68%
Forward P/E-EPS next Y-4.37%
PEG-EPS past 5Y6.26%
P/S18358.88EPS next 5Y-1.15%
P/B0.85EPS Q/Q44.15%
Dividend-Sales Q/Q-100.00%
Insider Own35.80%Inst Own63.64%
Insider Trans-0.26%Inst Trans-3.52%
Short Float28.03%EarningsMar 13/a
Analyst Recom1.44Target Price8.92
Avg Volume5.44M52W Range1.32 - 4.74
Mar-14-25 03:00PM Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... (GuruFocus.com)
Mar-13-25 04:11PM Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -8.25%
04:02PM Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Mar-03-25 08:30AM Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) -7.69%
Feb-26-25 08:30AM Allogene Therapeutics Announces Participation in March Investor Conference (GlobeNewswire)
Feb-25-25 04:10PM Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia (GlobeNewswire) -7.24%
Feb-13-25 04:30PM Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology (GlobeNewswire) +44.68%
Feb-04-25 08:30AM Allogene Therapeutics Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-29-25 08:30AM Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer (GlobeNewswire)
Jan-28-25 08:30AM Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases (GlobeNewswire)
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chang David DPresident and CEOMar 14 '25Sale1.9646,66891,4695,276,569Mar 18 05:30 PM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 14 '25Sale1.985,48810,839218,507Mar 18 05:28 PM
Beneski Benjamin MachinasOfficerMar 14 '25Proposed Sale1.975,48810,839Mar 14 04:58 PM
Chang David DOfficerMar 14 '25Proposed Sale1.9646,66891,469Mar 14 04:57 PM
MESSEMER DEBORAH M.DirectorFeb 18 '25Sale2.4313,31332,351144,316Feb 20 04:15 PM
BIOX - Bioceres Crop Solutions Corp - Stock Price Chart
TickerBIOX [NASD]
CompanyBioceres Crop Solutions Corp
CountryArgentina
IndustryAgricultural Inputs
Market Cap265.27MEPS (ttm)0.01
P/E295.80EPS this Y-177.18%
Forward P/E15.48EPS next Y464.44%
PEG3.31EPS past 5Y-
P/S0.65EPS next 5Y89.38%
P/B0.85EPS Q/Q35.29%
Dividend-Sales Q/Q-23.90%
Insider Own46.80%Inst Own21.18%
Insider Trans0.00%Inst Trans-12.05%
Short Float3.71%EarningsFeb 11/a
Analyst Recom1.00Target Price7.88
Avg Volume293.14K52W Range3.68 - 13.18
Bioceres Crop Solutions Corp. engages in the provision of crop productivity solutions. The firm includes seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. It operates through the following segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment deals with the development and commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments in order to increase crop productivity and create value for customers. The Crop Protection segment develops and produces adjuvants, insecticides and fungicides. The Crop Nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops and of fertilizers including bio fertilizers and micro granulated fertilizers that increases the productivity and yield of the crops. The company was founded on November 14, 2017 and is headquartered in Rosario, Argentina.
PYXS - Pyxis Oncology Inc - Stock Price Chart
TickerPYXS [NASD, RUT]
CompanyPyxis Oncology Inc
CountryUSA
IndustryBiotechnology
Market Cap63.03MEPS (ttm)-1.05
P/E-EPS this Y6.31%
Forward P/E-EPS next Y10.78%
PEG-EPS past 5Y-118.72%
P/S3.90EPS next 5Y2.73%
P/B0.41EPS Q/Q37.39%
Dividend-Sales Q/Q-
Insider Own28.94%Inst Own40.70%
Insider Trans0.52%Inst Trans-30.30%
Short Float16.59%EarningsMar 18/b
Analyst Recom1.33Target Price7.00
Avg Volume673.10K52W Range0.99 - 6.18
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connealy Pamela AnnCFO & COONov 26 '24Buy1.9688,850174,3641,199,143Nov 27 05:09 PM
FDMT - 4D Molecular Therapeutics Inc - Stock Price Chart
TickerFDMT [NASD, RUT]
Company4D Molecular Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap176.87MEPS (ttm)-3.16
P/E-EPS this Y-18.70%
Forward P/E-EPS next Y-8.52%
PEG-EPS past 5Y-9.89%
P/S4421.79EPS next 5Y-4.47%
P/B0.34EPS Q/Q-346.93%
Dividend-Sales Q/Q-100.00%
Insider Own14.40%Inst Own92.16%
Insider Trans-0.01%Inst Trans-23.77%
Short Float13.22%EarningsFeb 28/b
Analyst Recom1.75Target Price33.82
Avg Volume922.39K52W Range3.73 - 36.25
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bizily ScottChief Legal OfficerSep 16 '24Option Exercise6.495003,2457,281Sep 18 05:46 PM
Bizily ScottChief Legal OfficerSep 16 '24Sale16.335008,1656,781Sep 18 05:46 PM
Bizily ScottChief Legal OfficerAug 19 '24Option Exercise6.495003,2457,281Aug 21 04:28 PM
Bizily ScottChief Legal OfficerAug 19 '24Sale15.005007,5006,781Aug 21 04:28 PM
Bizily ScottChief Legal OfficerJul 16 '24Option Exercise7.601,75013,2958,531Jul 18 08:22 PM
NB - NioCorp Developments Ltd - Stock Price Chart
TickerNB [NASD]
CompanyNioCorp Developments Ltd
CountryUSA
IndustryOther Industrial Metals & Mining
Market Cap84.74MEPS (ttm)-0.19
P/E-EPS this Y38.46%
Forward P/E-EPS next Y-18.75%
PEG-EPS past 5Y1.47%
P/S-EPS next 5Y-4.89%
P/B11.47EPS Q/Q89.03%
Dividend-Sales Q/Q-
Insider Own8.85%Inst Own7.44%
Insider Trans0.00%Inst Trans51.81%
Short Float1.87%EarningsFeb 26
Analyst Recom1.00Target Price3.62
Avg Volume281.13K52W Range1.27 - 4.00
NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Southeast Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.
CSAI - Cloudastructure Inc - Stock Price Chart
TickerCSAI [NASD]
CompanyCloudastructure Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap86.10MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B179.79EPS Q/Q22.13%
Dividend-Sales Q/Q182.61%
Insider Own3.69%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float1.47%Earnings-
Analyst Recom-Target Price-
Avg Volume991.38K52W Range4.22 - 52.43
Cloudastructure, Inc. engages in the provision of cloud-based artificial intelligence video surveillance and remote guarding solutions. Its solutions include AI Surveillance, Remote Guarding, and Mobile Surveillance. The company was founded by Rick Bentley on March 28, 2003 and is headquartered in Palo Alto, CA.
TECX - Tectonic Therapeutic Inc - Stock Price Chart
TickerTECX [NASD]
CompanyTectonic Therapeutic Inc
CountryUSA
IndustryBiotechnology
Market Cap404.25MEPS (ttm)-9.73
P/E-EPS this Y55.24%
Forward P/E-EPS next Y35.14%
PEG-EPS past 5Y-
P/S-EPS next 5Y31.76%
P/B2.15EPS Q/Q79.31%
Dividend-Sales Q/Q-
Insider Own42.48%Inst Own40.05%
Insider Trans17.10%Inst Trans61.87%
Short Float8.90%EarningsNov 07/a
Analyst Recom1.00Target Price85.67
Avg Volume327.75K52W Range13.80 - 61.07
Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SPRINGER TIMOTHY ADirectorFeb 05 '25Buy50.00660,00033,000,000970,223Feb 07 04:21 PM
SPRINGER TIMOTHY ADirectorFeb 05 '25Buy54.14129,2946,999,9774,226,058Feb 07 04:21 PM
Lochner DanielChief Financial OfficerFeb 05 '25Buy54.144,617249,9644,617Feb 07 04:19 PM
Schwabish MarcChief Business OfficerJan 28 '25Option Exercise2.382,7006,4264,700Jan 29 04:05 PM
Schwabish MarcChief Business OfficerDec 09 '24Option Exercise2.382,0004,7602,000Dec 11 04:21 PM
IRBT - Irobot Corp - Stock Price Chart
TickerIRBT [NASD, RUT]
CompanyIrobot Corp
CountryUSA
IndustryFurnishings, Fixtures & Appliances
Market Cap105.67MEPS (ttm)-4.84
P/E-EPS this Y65.76%
Forward P/E-EPS next Y36.07%
PEG-EPS past 5Y-
P/S0.16EPS next 5Y-
P/B1.73EPS Q/Q-10.57%
Dividend-Sales Q/Q-43.36%
Insider Own6.34%Inst Own59.15%
Insider Trans0.00%Inst Trans-11.43%
Short Float18.07%EarningsMar 12/b
Analyst Recom3.00Target Price11.94
Avg Volume2.48M52W Range2.98 - 14.51
iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JULIE ZEILEROfficerMar 17 '25Proposed Sale3.702901,073Mar 17 04:26 PM
JULIE ZEILEROfficerDec 17 '24Proposed Sale8.923663,265Dec 17 04:29 PM
ZEILER JULIEEVP, Chief Financial OfficerSep 16 '24Sale7.294513,288117,604Sep 17 05:20 PM
JULIE ZEILEROfficerSep 16 '24Proposed Sale7.244513,263Sep 16 04:34 PM
Cohen GaryPresident & CEOMay 15 '24Buy12.292,05025,1892,150May 16 04:12 PM
ATNM - Actinium Pharmaceuticals Inc - Stock Price Chart
TickerATNM [AMEX, RUT]
CompanyActinium Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap37.12MEPS (ttm)-1.40
P/E-EPS this Y34.00%
Forward P/E-EPS next Y-1.69%
PEG-EPS past 5Y22.80%
P/S463.99EPS next 5Y13.33%
P/B0.97EPS Q/Q24.11%
Dividend-Sales Q/Q-
Insider Own2.54%Inst Own28.73%
Insider Trans0.00%Inst Trans-2.88%
Short Float7.39%EarningsMar 14
Analyst Recom1.00Target Price5.75
Avg Volume221.37K52W Range1.03 - 10.24
Today 08:00AM Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO (PR Newswire) -8.46%
Mar-17-25 08:50AM Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia (PR Newswire) +5.69%
Mar-12-25 08:00AM Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference (PR Newswire)
Mar-11-25 08:30AM Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML (PR Newswire)
Nov-18-24 08:00AM Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 (PR Newswire) -5.33%
Nov-14-24 07:02PM Actinium: Q3 Earnings Snapshot (Associated Press Finance) -9.09%
Nov-04-24 07:30AM Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-18-24 12:00PM All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy (Zacks) +5.81%
Sep-23-24 04:52AM Actinium Pharmaceuticals reports data from Phase III trial of AML treatment (Clinical Trials Arena)
Sep-20-24 08:00AM Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology (PR Newswire)
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
FUFU - BitFuFu Inc - Stock Price Chart
TickerFUFU [NASD]
CompanyBitFuFu Inc
CountrySingapore
IndustryCapital Markets
Market Cap688.31MEPS (ttm)0.24
P/E17.87EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S1.89EPS next 5Y-
P/B5.87EPS Q/Q-173.10%
Dividend-Sales Q/Q-
Insider Own90.04%Inst Own0.44%
Insider Trans0.00%Inst Trans-66.22%
Short Float2.44%EarningsNov 05/b
Analyst Recom1.00Target Price7.00
Avg Volume150.46K52W Range2.32 - 7.39
BitFuFu Inc. engages in providing digital asset mining and cloud-mining services. The firm fosters a secure, compliant, and transparent blockchain infrastructure, providing a variety of stable and intelligent digital asset mining solutions to a global customer base. It leverages a global mining facility network and strategic partnership with Bitmain, which enables institutional customers and digital asset enthusiasts to mine digital assets. The company was founded by Leo Lu in December 2020 and is headquartered in Singapore.
167891011121314151620